Table 1 Basic information on COVID-19 vaccination in Korea, Japan and Singapore
From: Comparison of COVID-19 vaccine policies and their effectiveness in Korea, Japan, and Singapore
| Â | Korea | Japan | Singapore |
|---|---|---|---|
Population (millions) | 51.27 | 12.65 | 5.85 |
Density of population(P/km2) | 359 | 390 | 8554 |
GDP per capita ($ million) | 3.22 | 4.13 | 8.27 |
Percentage of population over 65Â years old(%) | 13.91 | 27.05 | 12.92 |
Expected life expectancy (years) | 83.03 | 84.63 | 83.62 |
Cumulative number of confirmed cases (/ million) | 603,348.77 | 272,420.29 | 424,296.73 |
Cumulative number of deaths (/ million) | 666.05 | 601.96 | 305.48 |
Start date of vaccination | February 26, 2021 | February 17, 2021 | December 30, 2020 |
Cumulative vaccinations (millions) | 129.65 | 385.75 | 14.72 |
COVID-19 vaccination rate(%) | 86.43 | 84.47 | 91.55 |
Share of people with fully vaccinated(%) | 85.64 | 83.40 | 90.85 |
Share of people only partly vaccinated(%) | 0.79 | 1.07 | 0.70 |
Share of people with booster vaccinated(%) | 79.76 | 141.71 | 78.77 |
Vaccines Appointment | Vaccine appointments are made online or by phone | Vaccine appointments are made online or by phone | Vaccine appointments are made online or by phone |
Free vaccination or not | Free vaccination for the entire population | Free vaccination for the entire population | Free vaccination for the entire population |
Vaccines administered | Pfizer/BioNTech, Moderna, AstraZeneca, Novavax, Johnson&Johnson | Pfizer/BioNTech, Moderna, AstraZeneca | Pfizer-BioNTech/Comirnaty Moderna/Spikevax Novavax/Nuvaxovid Sinovac-CoronaVac |